← Back to Search

Dietary Supplement

NAD+ Supplement for Brain Function

Kingston, RI
N/A
Recruiting
Research Sponsored by University of Rhode Island
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Taking hormone medication
Timeline
Screening 3 weeks
Treatment Varies
Follow Up four weeks
Awards & highlights
No Placebo-Only Group

Summary

"This trial aims to see if NAD+ can improve brain function and biomarkers in healthy Latina women aged 40-80. They will compare those taking NAD+ to those taking a placebo.

See full description
Who is the study for?
This trial is for Latina women aged 40-80 who are healthy and cognitively intact, have experienced three or more adverse childhood events, and have a BMI of at least 18.5. It's not open to those on hormone medication, or who are pregnant or breastfeeding.Check my eligibility
What is being tested?
Researchers are testing if NAD+ supplements can improve brain function (like planning and decision-making) and reduce markers of inflammation and neurodegeneration in the blood compared to a placebo over four weeks.See study design
What are the potential side effects?
Potential side effects aren't detailed here but could include reactions similar to other oral supplements such as digestive discomfort, skin rash, fatigue, or headaches.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently taking hormone medication.
 show original

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~four weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and four weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Markers of systemic inflammation
Neurocognition
Neurodegenerative disease panel

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment1 Intervention
For four weeks, the participant will consume an oral supplement, either Nicotinamide adenine dinucleotide or a placebo.
Group II: Pre-testing prior to interventionActive Control1 Intervention
Prior to receiving the supplement, either Nicotinamide adenine dinucleotide or the placebo, participants will undergo cognitive testing and a blood draw.
Group III: Post-testing after interventionActive Control1 Intervention
After receiving the supplement, either Nicotinamide adenine dinucleotide or the placebo, participants will undergo cognitive testing and a blood draw.

Find a Location

Closest Location:University of Rhode Island· Kingston, RI· 611 miles

Who is running the clinical trial?

University of Rhode IslandLead Sponsor
56 Previous Clinical Trials
22,321 Total Patients Enrolled
National Institute of General Medical Sciences (NIGMS)NIH
309 Previous Clinical Trials
250,161 Total Patients Enrolled
~10 spots leftby May 2025